资金流向方面，主力资金净流出864.51万元，特大单买入0.00元，占比0.00%，卖出370.89万元，占比 5.52%；大单买入471.32万元，占比7.01%，卖出964.94万元，占比14.36%。 济川药业今年以来股价跌8.30%，近5个交易日跌2.48%，近20日跌3.51%，近60日跌10.29%。 资料显示，湖北济川药业股份有限公司位于江苏省泰兴市大庆西路宝塔湾，成立日期1997年1月22日， 上市日期2001年8月22日，公司主营业务涉及药品的研发、生产和销售。主营业务收入构成为：中药 77.82%，西药19.27%，其他2.66%，其他(补充)0.25%。 济川药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：医药电商、中药、抗流感、 多胎概念、生物医药等。 10月23日，济川药业盘中下跌2.06%，截至13:00，报24.76元/股，成交6719.85万元，换手率0.29%，总 市值227.96亿元。 截至6月30日，济川药业股东户数4.40万，较上期增加4.69%；人均流通股20834股，较上期减少4.48%。 2025年1月-6月，济川药业实现营业收入27.49亿元，同 ...

济川药业 20251017 摘要 济川药业当前股价位置具有较高性价比，未来趋势向好，投资者可重点 关注和配置。 2025 年 7 月推出的即可舒已获京东健康线上销售许可，预计四季度流 感发病率增加将推动其销量增长。 公司还有 PDE4 和长效生长激素等在研管线处于后期阶段，其研发进展 值得关注。 蒲地蓝消炎口服液重点开拓院外市场，小儿豉翘清热颗粒是独家儿科品 种，二者均为非基药品种，但符合国家鼓励方向。 公司拥有黄龙止咳颗粒、三拗片、柴胡颗粒等二线品种，构成呼吸道领 域强大的产品矩阵，巩固公司在 OTC 渠道和儿科领域的领先地位。 截至目前，公司账上现金接近百亿级别，2024 年分红比例达到 76%。 9 月份国家基本药物管理办法修订稿形成实质性进展，预计四季度或明 年两会后将进一步推进，可能带来院内量的提升，市场预期尚不充分。 Q&A 济川药业在 2025 年第三季度的业绩表现如何？ 济川药业在 2025 年 7 月推出了即可舒产品，并获得京东健康线上销售许可。 预计今年四季度流感发病率增加，将推动该产品销量。此外，公司还有 PDE4 和长效生长激素等在研管线处于后期阶段，值得关注其进展。 济川药业的主要产 ...

Core Viewpoint - The launch of the innovative anti-influenza drug Jike Shou (generic name: Marcilosavir tablets) on JD Health's platform enhances its accessibility and convenience for influenza treatment [1] Company Summary - Jike Shou is a domestically developed drug in China with global intellectual property rights, acting as a targeted RNA polymerase PA inhibitor for influenza viruses [1] - In 2023, the company formed a strategic partnership with Zhengxiang Pharmaceutical for exclusive promotion and sales rights of Jike Shou in China [1] - The drug received approval from the National Medical Products Administration for market launch in July 2025 [1] Industry Summary - The collaboration with JD Health is seen as a strong alliance to accelerate the availability of innovative drugs to the public, leveraging JD Health's professional supply chain and user reach capabilities [1] - The company aims to enhance the consumer experience through improved product offerings, efficient fulfillment, and comprehensive service guarantees [1]

证券日报网讯济川药业（600566）10月15日在互动平台回答投资者提问时表示，小儿豉翘清热糖浆(基 于小儿豉翘清热颗粒的改良型新药)于2023年11月获批上市，目前已在京东等线上平台有售，进院工作 也在稳步推进中。研究结果表明小儿豉翘清热糖浆治疗小儿风热感冒夹滞证的疗效非劣于已上市品种小 儿豉翘清热颗粒，糖浆剂型服用方便、口味更佳、药物吸收好，为儿科患者用药带来新选择，更好地满 足了儿童差异化的用药需求。 ...

Core Points - The announcement pertains to the stock option incentive plan of Hubei Jichuan Pharmaceutical Co., Ltd. for 2022, detailing the first grant of stock options and the exercise period [1][2] - The actual exercise period for the first grant of stock options is set from October 15, 2025, to September 7, 2026 [1] - There will be a restriction on exercising options from October 23, 2025, to October 27, 2025, during which all incentive participants will be restricted from exercising their options [2] Summary by Sections - **Incentive Plan Overview** - The company is implementing a stock option incentive plan as per relevant regulations and guidelines [1] - **Exercise Period Details** - The first exercise period for the stock options is confirmed to be from October 15, 2025, to September 7, 2026 [1] - **Restriction Period** - A specific restriction period for exercising options is established from October 23, 2025, to October 27, 2025 [2]

Core Viewpoint - The Chinese medicine sector shows resilience with the Chinese Medicine ETF (560080) rising by 0.28% despite market fluctuations, indicating strong investor interest and a net inflow of over 220 million yuan in the past 10 days [1][3]. Market Performance - The Chinese Medicine ETF (560080) has maintained a premium, closing with a premium rate of 0.14%, and has seen a total trading volume exceeding 1 billion yuan [1]. - Major stocks within the ETF, such as Dong'e Ejiao and Yunnan Baiyao, have shown positive performance, with Dong'e Ejiao increasing by over 1% [3][4]. Index Performance - The Chinese medicine index has experienced a negative return of -2.86% year-to-date, with a decline of 8.13% projected for 2024 [4]. - The index has shown a pattern of alternating performance, with three consecutive years of gains from 2019 to 2021, followed by three years of declines from 2016 to 2018 [4]. Valuation Metrics - The TTM price-to-earnings ratio for the Chinese Medicine ETF (560080) stands at 24.86, placing it at the 20.6% percentile of the past decade, suggesting a favorable valuation [6]. Financing and Investment Trends - Leveraged funds are increasingly utilizing the ETF for exposure to the higher-value Chinese medicine consumer sector, with the latest financing balance exceeding 91 million yuan, maintaining historical highs [7]. - The overall sentiment in the Chinese medicine sector is expected to improve, driven by stable market demand and accelerated innovation [9]. Future Outlook - The Chinese medicine sector is anticipated to benefit from innovation and transformation, with a focus on new product development and cost reductions in raw materials [9][10]. - The sector is positioned to leverage its advantages in preventive healthcare and as a complementary treatment alongside Western medicine [10]. Corporate Governance and Incentives - Recent corporate governance improvements and incentive plans in state-owned enterprises are expected to drive growth in the Chinese medicine sector, with companies like Huaren Sanjiu and Jiangzhong Pharmaceutical implementing effective incentive programs [11][12]. Dividend Yield - Several Chinese medicine companies are projected to have dividend yields exceeding 3% in 2024, with state-owned enterprises leading in this regard, indicating strong cash flow and shareholder returns [13][14].

湖北济川药业股份有限公司 一、公司 2022 年限制性股票与股票期权激励计划首次授予股票期权第一个 行权期（期权代码：1000000228）实际可行权期间为 2025 年 10 月 15 日至 2026 年 9 月 7 日。 二、本次限制行权期为 2025 年 10 月 23 日-2025 年 10 月 27 日，在此期间全 部激励对象将限制行权。 三、公司将按照有关规定及时向中国证券登记结算有限责任公司上海分公司 申请办理限制行权相关事宜。 证券代码：600566 证券简称：济川药业 公告编号： 2025-089 关于 2022 年限制性股票与股票期权激励计划 首次授予股票期权限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股权激励管理办法》《上海证券交易所上市公司自律监管指 南第 2 号——业务办理》《湖北济川药业股份有限公司 2022 年限制性股票与股票 期权激励计划》及中国证券登记结算有限责任公司上海分公司关于股票期权自主 行权的相关规定，并结合湖北济川药业股份有限公司（以下简称 ...

Core Viewpoint - Jichuan Pharmaceutical is focusing on enhancing its brand and offline coverage for its daily chemical products, with significant progress in terminal store coverage and product approvals [1] Group 1: Product Development and Approval - Pudilan Oral Liquid has been approved in 2024 as a dual-category drug, allowing it to be classified as both a prescription and an over-the-counter medication. The OTC packaging is now available in major retail pharmacies nationwide [1] - The new chemical drug, Marcilosavir Tablets, developed in collaboration with Nanjing Zhengxiang Pharmaceutical Co., Ltd., received approval in July 2025. This product is designed to alleviate flu symptoms with a single oral dose, although it will require a market development period before launch [1] Group 2: Market Strategy - The company emphasizes brand building and offline coverage for its daily chemical products by precisely targeting core markets, deepening existing customer engagement, and expanding new customer acquisition through a replicable benchmark model [1] - The offline terminal coverage has reached thousands of stores, indicating a strong commitment to increasing market presence [1]

证券代码：600566 证券简称：济川药业 公告编号： 2025-088 湖北济川药业股份有限公司 关于 2022 年限制性股票与股票期权激励计划 首次授予股票期权第一个行权期自主行权实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 股票期权拟行权数量：1,714,800份 行权股票来源：向激励对象定向发行本公司 A 股普通股 行权起始日期：2025年10月15日。 事宜的议案》。律师事务所出具相应法律意见。 重要内容提示： 湖北济川药业股份有限公司（以下简称"公司"）2025 年 9 月 9 日召开第十 届董事会第十七次会议，审议通过了《关于 2022 年限制性股票与股票期权激励 计划首次授予部分第一个解除限售期解除限售条件及第一个行权期行权条件成 就的议案》，公司 2022 年限制性股票与股票期权激励计划（以下简称"本激励计 划"）首次授予股票期权的第一个行权期行权条件已成就。 经上海证券交易所及中国证券登记结算有限责任公司上海分公司审核，以上 期权将于 2025 年 10 月 15 日开始可以行权。本次可以 ...

Core Viewpoint - Jichuan Pharmaceutical's Q2 revenue decreased by 25.03% year-on-year to 1.223 billion yuan, primarily due to a high base effect from the previous year in the respiratory product category [1] - The company reported a net profit attributable to shareholders of 284 million yuan, down 42.39% year-on-year, and a net profit excluding non-recurring items of 228 million yuan, down 49.70% year-on-year, indicating significant pressure on profitability due to declining terminal demand for core products [1] - The company expects a recovery in demand for respiratory products in the second half of the year, supported by the seasonal increase in respiratory diseases, and will continue to focus on the development and launch of new products [1] Financial Performance - Q2 revenue was 1.223 billion yuan, a decline of 25.03% year-on-year [1] - Net profit attributable to shareholders was 284 million yuan, a decrease of 42.39% year-on-year [1] - Net profit excluding non-recurring items was 228 million yuan, down 49.70% year-on-year [1] Market Outlook - The company anticipates a recovery in terminal sales in the second half of the year as inventory levels for core respiratory products have returned to reasonable levels [1] - The upcoming high season for respiratory diseases is expected to boost demand [1] - Continuous progress in the research and development of new product pipelines is a focus for the company [1]